# ImmunityBio Inc. (IBRX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.08, market value $8.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). ImmunityBio Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 51.7×**. Each dollar of revenue is priced at 51.7×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -3.4%** (5-yr avg -17.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -151.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -310.2%**. The company reported a net loss over the last twelve months.
- **Return on equity: 70.2%**. A 70.2% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 33.9%**. Return on all capital, debt included, is 33.9%: comfortably above what that capital costs.
- **Return on assets: -197.7%**. Each dollar of assets produces -197.7% of profit.

## Growth
- **Revenue growth (1 yr): 668.3%** (3-yr 678.6%/yr, 5-yr 184.8%/yr). Revenue grew 668.3% over the last year, against 184.8% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 38.7%**. Earnings per share rose 38.7%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: 0.4×**. It would take 0.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 2.28**. A Z-score of 2.28 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. ImmunityBio Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 238.1%** (YTD 308.1%, 3-mo 16.8%). The shares are up 238.1% over twelve months including dividends.
- **From 52-week high: -35.0%** (314.4% above the low). Trading 35% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 1.73** (volatility 104%). Beta of 1.73 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IBRX · Page: https://foliofundamentals.com/stocks/ibrx

Not investment advice.